Highest-materiality recent filing
Sera Prognostics director Jeff Elliott resigns ahead of annual meeting
Jeff Elliott notified Board of resignation effective June 4, 2026; not due to any disagreement.
Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births
Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.
Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks
Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
Sera Prognostics posts investor presentation; no material updates disclosed
Presentation posted on Jan 8, 2026; only title slide 'Redefining pregnancy care to reduce preterm birth' available.
PRIME study: PreTRM blood test cuts preterm births <32 wks by 56%, NICU admissions by 20%
Randomized trial of 5,018 women: 56% fewer births <32 wks, 32% fewer <35 wks.
Sera Prognostics announces PRIME preterm-birth study accepted for peer-reviewed publication
PRIME study findings accepted for publication, following late-breaking abstract at SMFM annual meeting in 2025.
Sera Q3 revenue $16k, net loss $7.8M; launches Medicaid pilot in Nevada
Revenue $16k vs $29k YoY; net loss $7.8M vs $7.9M; cash $102.4M funds operations through 2028.
Sera Prognostics posts investor presentation at H.C. Wainwright conference
New investor presentation posted to corporate website on September 5, 2025.
Sera Prognostics Q2 revenue $17K, net loss $8.0M, PreTRM progress
Revenue $17,000 vs $24,000 in Q2 2024; net loss $8.0M vs $8.3M.
Sera Prognostics announces annual meeting results; directors elected, auditor ratified
Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. elected as Class I directors for three-year terms.
Lee Anderson appointed CCO effective May 8, 2025; reports to CEO Zhenya Lindgardt.
Sera Prognostics Q1 revenue $38k, net loss $8.2M; payor discussions advance
Revenue of $38k vs nil in prior year; net loss $8.2M vs $8.1M.
Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M
Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.
Sera Prognostics prices $50M public offering of 1.25M shares and 11.25M pre-funded warrants
Offering priced at $4.00 per share of Class A common stock and $3.9999 per pre-funded warrant.
Sera Prognostics terminates unused $50M ATM offering program
No shares of Class A common stock were sold under the ATM offering since its August 2024 inception.
Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M
Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
Sera Prognostics files 8-K for new investor presentation at J.P. Morgan Healthcare Conference
Company posted updated investor presentation to its website on January 13, 2025.
Sera Prognostics PRIME study topline results published by SMFM
SMFM published an abstract of topline results for the PRIME study on preterm birth risk assessment.
Sera Prognostics Q3 revenue $29k, net loss $7.9M; PRIME study data locked
Revenue fell to $29k from $42k YoY; net loss widened to $7.9M from $7.2M.
Sera Prognostics Q2 2024 net loss narrows to $8.3M; revenue drops to $24k
Q2 2024 revenue was $24,000, down from $123,000 in Q2 2023.
Sera Prognostics annual meeting elects directors, ratifies auditor
Quorum of 20,402,055 shares (64.4% of eligible) present at June 6, 2024 annual meeting.
Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026
Max materiality 0.85 · Median 0.50 · Most common event other_material